Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 8,270,000 shares, an increase of 15.8% from the October 15th total of 7,140,000 shares. Approximately 11.4% of the company’s stock are short sold. Based on an average daily volume of 463,300 shares, the short-interest ratio is presently 17.9 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the 3rd quarter valued at $27,000. XTX Topco Ltd boosted its stake in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after acquiring an additional 15,376 shares in the last quarter. SG Americas Securities LLC grew its holdings in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after purchasing an additional 25,201 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd in the 2nd quarter valued at $86,000. Finally, Rhumbline Advisers raised its holdings in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares during the period. Institutional investors own 70.36% of the company’s stock.

Invivyd Stock Down 4.5 %

Invivyd stock traded down $0.04 during mid-day trading on Friday, hitting $0.76. 563,067 shares of the company’s stock traded hands, compared to its average volume of 632,977. Invivyd has a one year low of $0.76 and a one year high of $5.20. The firm has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.30. The company has a market cap of $90.19 million, a PE ratio of -0.39 and a beta of 0.65.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.91 million. On average, analysts expect that Invivyd will post -0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Invivyd in a research note on Tuesday, October 29th.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.